Bevacizumab (Avastin) pour le cancer de l’ovaire résistant aux sels de platine — Détails

Détails

Fichiers
Generic Name:
Bevacizumab
État du projet:
Terminé
Domaine thérapeutique:
Platinum Resistant Ovarian Cancer
Fabricant:
Hoffmann-La -Roche Limited
Brand Name:
Avastin
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0066-000
Statut de l’AC au moment du dépôt:
Post AC
Strength:
25mg/mL
Tumour Type:
Gynécologique
Indications:
Platinum-Resistant Ovarian Cancer
Funding Request:
In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Date NOC Issued:
Sponsor:
Hoffmann-La -Roche Limited
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Demandée et refusée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.